Related Experiment Video
Updated: Jul 13, 2026
07:49
Intracerebroventricular Delivery of Gut-Derived Microbial Metabolites in Freely Moving Mice
Published on: June 2, 2022
Serotonin and neuroprotection in functional bowel disorders
1Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA. mdg4@columbia.edu
Neurogastroenterology and Motility
|August 31, 2007
Summary
Serotonin 5-HT(4) receptor agonists, like tegaserod, protect and nourish gut neurons. This neuroprotective action may prevent age-related digestive motility disorders.
Area of Science:
- Neuroscience
- Gastroenterology
- Pharmacology
Background:
- The 5-HT(4) receptor is a key player in the enteric nervous system, regulating gastrointestinal motility.
- Tegaserod, a 5-HT(4) partial agonist, is used to treat chronic constipation and irritable bowel syndrome with constipation.
- Age-related decline in enteric neurons may contribute to gastrointestinal dysmotility in the elderly.
Purpose of the Study:
- To investigate the neuroprotective and neurotrophic effects of 5-HT(4) receptor agonists on enteric neurons.
- To explore the potential of 5-HT(4) agonists in preventing age-related gastrointestinal motility disorders.
Main Methods:
- Studied the effects of 5-HT(4) receptor agonists (tegaserod, RS67506) and antagonist (GR113808) on enteric neurons in vitro and in vivo (using knockout mice).
- Assessed neuronal survival, development from precursor cells, neurite outgrowth, and apoptosis.
- Examined the impact of 5-HT(4) receptor knockout on gastrointestinal activity and neuronal loss in aging mice.
Main Results:
- 5-HT(4) receptor agonists increased the number and size of enteric neurons, promoted neurite outgrowth, and reduced apoptosis.
- Knockout of 5-HT(4) receptors led to slower gastrointestinal activity and increased age-related neuronal loss.
- The effects of agonists were blocked by the 5-HT(4) antagonist, confirming specificity.
Conclusions:
- 5-HT(4) receptor agonists exhibit significant neuroprotective and neurotrophic properties for enteric neurons.
- These findings suggest a potential therapeutic role for 5-HT(4) agonists in mitigating age-related gastrointestinal dysmotility.
- Further investigation into the clinical application of 5-HT(4) agonists for age-related enteroneuropathies is warranted.
Related Concept Videos
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
01:22Gut-Brain Axis
The gut–brain axis is a bidirectional communication system that connects the gastrointestinal tract and the brain. This interaction is mediated through multiple pathways, including the vagus nerve, hormonal signals, immune responses, and chemical messengers produced by gut microbes.Microbial Contributions to Brain FunctionGut microbiota contributes significantly to brain function by producing neuroactive compounds. These include neuroactive compounds that influence neurotransmitters such as...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:17Irritable Bowel Syndrome I: Introduction
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:23Irritable Bowel Syndrome
DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are: